Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382240 | 0.89 | TTK (0.46) | ACKR3LRRK2PARP1NPC1 | |
| SCHEMBL13006036 | 0.88 | ACKR3 (0.47) | ACKR3LRRK2PARP1AURKB | |
| SCHEMBL3770059 | 0.84 | ACKR3 (0.49) | ACKR3NPC1 | |
| SCHEMBL13006033 | 0.83 | ACKR3 (0.47) | ACKR3LRRK2PARP1 | |
| SCHEMBL13006042 | 0.83 | ACKR3 (0.42) | ACKR3LRRK2PARP1 | |
| SCHEMBL3763689 | 0.82 | LRRK2 (0.44) | LRRK2PARP1 | |
| SCHEMBL3778715 | 0.81 | MEN1 (0.44) | LRRK2PARP1NPC1KMT2A | |
| SCHEMBL3763692 | 0.80 | LRRK2 (0.48) | LRRK2PARP1 | |
| SCHEMBL3775033 | 0.80 | SIRT2 (0.46) | ACKR3LRRK2PARP1 | |
| SCHEMBL3762154 | 0.80 | LRRK2 (0.53) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | ACKR3 125/4885EPHX2 2006/4885LRRK2 2309/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | ACKR3 124/4885EPHX2 1983/4885LRRK2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.